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Introduction . Lymph node involvement is a negative prognostic factor for patients undergoing curative gastrectomy 
and indication for preoperative chemotherapy, thus a sufficient assessment strategy is required. We aimed to establish 
the value of preoperatively collected data in prediction of lymph node metastasis.
Material and methods . We conducted a retrospective analysis of 150 gastric cancer patients hospitalized in the Depart-
ment of Surgical Oncology, Medical University of Łódź in 2011–2017. We gathered information comprising clinicopatho-
logical features, inflammatory markers: neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), systemic 
inflammatory response index (SIRI) and Tumor Index (TI). 
Results . Independent factors associated with lymph node involvement were: NLR (OR = 1.35; p = 0.01), Tumor Index 
(OR = 1.07; p < 0.001). ROC curve plots assessed the diagnostic value of TI and NLR. 
Conclusions . Tumor Index and NLR are factors indicating lymph node metastasis in gastric cancer patients. NLR is a po-
tentially useful tool for neoadjuvant chemotherapy qualification.
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Introduction
Despite consistent decrease in incidence and mortality, ga-
stric cancer remains the third leading cause of cancer death 
worldwide. Five-year survival ranges between 20% and 70% 
in different regions of the world [1, 2]. Poor prognosis and lack 
of targeted therapies make surgery still the main and the most 
important treatment option [3, 4]. Due to high recurrence 
rate, even after curative resection, adjuvant therapy is a part 
of routine treatment [2]. 
Recently, several trials revealed that neoadjuvant che-
motherapy improves patient survival [5–8]. Combination of 
pre- and postoperative chemotherapy is recommended in ad-
vanced stages, especially those with lymph node metastases 
[3, 4, 9]. Wide range of tools and techniques for lymph node 
assessment, such as endoscopic ultrasonography, computed 
tomography or MRI is available, but their clinical value is 
questionable because of their inconsistent results [4, 10–12]. 
Several biomarkers connected with lymph node metastases 
have been considered, however, up to date none of them 
have proven their usefulness in routine clinical practice. The 
role of systemic inflammatory response and tumor microenvi-
ronment in cancer progression and promotion of metastasis 
has been widely explored [13, 14]. Leukocyte infiltration and 
inflammation is the key part of physiological response to 
tumor growth in gastric cancer [15, 16]. The moment when 
tumor factors overcome systemic response and affect cyto-
kine and chemokine production, together with leukocyte 
differentiation, is probably when the growing neoplasm gains 
metastatic ability [17–20].  This complex interaction is reflec-
ted in peripheral blood count and acute-phase proteins level. 
Several systemic inflammatory markers, including neutro-
phil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio 
(PLR), monocyte-to-lymphocyte ratio (MLR) and Systematic 
Inflammatory Response Index (SIRI), have been established 
8as independent prognostic factors in many different cancers 
(21–25). Tumor Index (TI) is a simple indicator, which combi-
nes depth and size of primary tumors [26]. While prognostic 
value in gastrointestinal neoplasms is widely explored, only 
few studies examined the role of preoperative markers in 
assessment of lymph node status [24, 25]. In this study we 
aimed to establish the value of preoperatively collected data: 
previously mentioned markers and clinicopathological data as 
preoperative predictors of lymph node metastasis in patients 
undergoing curative surgery for gastric cancer.
Material and methods 
Patients, collected data and inclusion criteria
We conducted a retrospective analysis of 350 consecutive 
gastric cancer patients hospitalized in the Department of Sur-
gical Oncology, Medical University of Łódź, between January 
2011 and December 2017; 150 of them underwent elective 
curative gastrectomy and fulfilled the study criteria. Out of the 
excluded patients, 139 accounted for non-curative resections, 
35 underwent neoadjuvant treatment, 5 had less than 15 
harvested lymph nodes and in 6 patients postoperative histo-
logical evaluation did not confirm adenocarcinoma diagnosis. 
Additionally, 13 patients presented with chronic and 2 with 
acute inflammatory diseases, which could influence laboratory 
blood test results. We gathered information comprising age, 
sex, tumor histopathological features, size and location, TNM 
stage, blood test results and course this of medical treatment. 
Histological type was assessed according to Lauren classifica-
tion (intestinal, diffuse and mixed type) and according to WHO 
classification of gastric tumors [8]. Patient characteristics are 
shown in Table I.
Definition of calculated markers
Laboratory measurements comprised full blood count (ery-
throcytes, platelets, neutrophils, lymphocytes, monocytes) 
and were performed 1–2 days before the surgery. Neutrophil 
to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), 
monocyte to lymphocyte ratio (MLR), systemic inflammatory 
response index (SIRI = neutrophil count × monocyte count/
lymphocyte count) and Tumor Index (TI = T from TNM stage 
category × tumor size in cm) were obtained.
Statistical analysis
We performed statistical analysis using SPSS 23. Univariate 
analysis was done to reveal statistically significant factors in-
dicating the presence of lymph node metastasis. Distribution 
normality of continuous variables was evaluated by Shapi-
ro-Wilk test. The difference between lymph node positive 
and lymph node negative groups in categorical variables was 
assessed using chi-squared test, in continuous normally distri-
buted variables using t-test and in continuous non-normally 
distributed variables using Mann-Whitney U test. P value < 0.05 
from univariate analysis was a criterion to include a variable 
in multivariate logistic regression to assess which of them 
were independent factors. We checked our model to meet 
key logistic regression assumptions: the observations were 
independent, there was no correlation between variables, the 
independent variables were linearly related to the log odds.
Receiver operating characteristic curves (ROC) were ob-
tained for the statistically significant continuous predictors. 
Sensitivity, specificity, positive and negative predictive values 
were calculated. Optimal cutoff values for ROC curves were 
calculated using Youden Index (sensitivity + specificity-1) [27]. 
P value < 0.05 was considered statistically significant.
Table I . Patient characteristics
Parameter Number of patients (%)
Age at the time of surgery
Median age (± SD) (65 ± 10.1)
Patient sex
Female 56 (37.4%)
Male 94 (62.6%)
Tumor stage
T1 25 (16.7%)
T2 19 (12.7%)
T3 75 (50%)
T4 31 (20.6%)
Lymph node involvement
N0 47 (38.2%)
N1 16 (13%)
N2 21 (17.1%)
N3 39 (31.7%)
Lauren classification
Intestinal type 69 (46%)
Diffuse type 50 (33.3%)
Mixed type 31 (20.7%)
WHO Classification
Tubular type 63 (42%)
Poorly cohesive carcinoma 55 (36.7%)
Other 32 (21.3%)
Localization
Body 92 (54.7%)
Pylorus 47 (31%)
Cardia 7 (4.7%)
Major part of the stomach 14 (9.3%)
Tumor size
Median size
mean (± SD)
4.9  
(5.05 ± 2.6)
Lymph node yield
Median yield 
mean (± SD)
26  
(27.8 ± 10.3)
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Univariate and multivariate analysis of 
clinicopathological characteristic and obtained 
markers 
Out of the considered variables NLR (p = 0.004), SIRI (p = 0.02), 
T feature according to TNM staging system (p = 0.001), Tumor 
Index (p < 0.001) and Lauren mixed type (p = 0.008) showed as-
sociation with the presence of lymph node metastasis (Tab. II).
There was no impact of age (p = 0.907), sex (p = 0.132), 
tumor size (p = 0.153), lymph node yield (p = 0.107), gra-
ding (p = 0.23), any blood cell count, PLR (p = 0.203) or MLR 
(p = 0.388) on lymph node status. Due to correlation and lack 
of independency between T stage and Tumor Index and be-
tween NLR and SIRI, we decided not to include T stage and SIRI 
in the multivariate analysis. NLR and TI as predictors explained 
more variation in lymph node status. The remaining statistically 
significant factors were included. 
Multivariate logistic regression revealed that independent 
factors associated with the presence of lymph node meta-
stasis were: NLR with OR = 1.35; 95% CI [1.08–1.7]; p = 0.009, 
Tumor Index (TI) with OR = 1.41; 95% CI [1.2–1.7]; p < 0.004 
and mixed-type by Lauren with OR = 3.85; 95% CI [1.12–13.2]; 
p = 0.033.
ROC curves and clinical value of markers
ROC curve analysis allowed to assess the diagnostic value of 
Tumor Index (AUC = 0.66; p < 0.001), cutoff point – 6 and NLR 
(AUC = 0.63; p = 0.002), cutoff point – 4.1. For TI, in our group 
113 (75.3%) patients were above the mentioned cutoff point. 
80 of them had lymph node metastasis reported in posto-
perative histopathological exam. Out of 37 patients below 
the cutoff point, 12 (37%) had lymph node involvement. This 
translates into 87% sensitivity, 43% specificity, 71% positive 
predictive value (PPV) and 67% negative predictive value (NPV). 
For NLR cutoff value of 4.1, associated with 35% sensitivity, 
90% specificity, 84% positive predictive value (PPV) and 46% 
negative predictive value (NPV).
Discussion
Gastric cancer is a major public health concern worldwide. 
Because of unspecific symptoms and screening programs per-
formed only in several Asian countries, stomach malignancies 
are usually diagnosed at advanced stages. In Europe surgery 
with D2 lymphadenectomy is a treatment-of-choice, however, 
surgery alone is associated with poor prognosis and high local 
recurrence rate [3, 4]. Therefore, various adjuvant treatment 
options have been developed, with postoperative chemo-
radiotherapy or chemotherapy alone being a treatment-of-
-choice for most patients after curative resection. Recently 
neoadjuvant chemotherapy is widely advocated, showing 
a survival benefit compared with surgery alone, with similar 
morbidity rates (2.5–9.28). Perioperative treatment, consisting 
of pre- and postoperative chemotherapy is becoming tre-
atment-of-choice for most patients diagnosed with gastric 
cancer at an advanced stage, resulting in overall survival be-
nefit [3, 9]. However, neoadjuvant treatment seems to be the 
Table II . Clinicopathological characteristics and lymph node metastases: univariate and multivariate analysis
Univariate analysis Multivariate analysis
Variable p value OR 95% CI p value
Mixed-type by Lauren 0.008 3.85 1.12–13.2 0.033
Tumor stage 0.001 – – –
Grading 0.23 – – –
Patient age 0.97 – – –
Tumor Index < 0.001 1.41 1.2–1.7 0.004
NLR 0.004 1.35 1.08–1.7 0.009
PLR 0.203 – – –
SIRI 0.02 – – –
MLR 0.388 – – –
0.0
0.0 0.2 0.4 0.6 0.8 1.0
0.2
0.4
0.6
0.8
1.0
1 – Specicity
Se
ns
iti
vi
ty
Tumor Index
NLR
Figure 1 . ROC curve plot for TI and NLR
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most effective in controlling nodal metastasis and results in 
increased R0 resection rates, therefore it is recommended for 
patients with present lymph node involvement in preoperative 
assessment [7]. Although some experts recommend routine 
preoperative chemotherapy in all patients with stage ≥ Sta-
ge IB, many consider this as patient overtreatment, resulting 
in unnecessary risk and questionable clinical benefits. Initial 
diagnostic methods recommended for routine preoperative 
staging comprise of: blood tests, classic endoscopy with biopsy 
and computed tomography (CT), provide little information 
about lymph node status. Low sensitivity of CT 62.5 (91% in 
systematic reviews) together with lack of global consensus 
on specific diagnostic criteria makes it a non-reliable source 
for nodal involvement evaluation [4, 10]. Multidetector-row 
computed tomography (MDCT), conventional magnetic reso-
nance imaging (MRI), positron emission tomography (PET-CT) 
are additional imaging options available for clinicians, their 
value, however, varies between different studies and cannot 
distinctly confirm or exclude presence of nodal metastases in 
gastric cancer patients [10]. Endoscopic ultrasonography (EUS) 
provides powerful ability to assess depth of primary tumor 
invasion, but it is less useful in predicting lymph node status. 
Considering still relatively low availability of EUS in routine 
practice in many places of the word, its practical value in gastric 
cancer staging is lower than expected [4, 11, 12].
In recent years several markers, derived from peripheral 
blood count levels, such as previously described NLR, PLR, 
MLR and SIRI, have been investigated and their prognostic 
value in many different cancers was reported. Few studies 
point out the connection between elevated PLR or NLR and 
presence of lymph node metastases in thyroid and gastric 
cancer [24, 25]. To the best of our knowledge, our study is the 
first to investigate this relation in the European population of 
gastric cancer patients. Out of systemic inflammation markers 
considered in our analysis, only NLR was an independent factor 
associated with the lymph node invasion. As described, this 
may originate from the tumor’s ability to create local metastasis 
by modulating local leukocyte differentiation, which leads to 
elevated neutrophil counts in peripheral blood [14–16, 19, 27]. 
There is no such documented association in platelets, which 
may explain why PLR, a widely reported prognostic factor, does 
not predict nodal metastasis. SIRI is a more complex marker 
incorporating monocyte, neutrophil and lymphocyte levels. 
While it is statistically significant as a single factor, we decided 
not to include it in multivariate analysis due to the correlation 
and lack of independency with NLR. NLR as a predictor expla-
ined more variation in lymph node status. In the recent years, 
some researchers investigated association between NLR or 
PLR and lymph node status. Zhang et al. concluded that both 
these markers are useful in predicting lymph node metastasis 
in gastric cancer patients [29]. Results of a similar study con-
ducted by Pang et al. suggested the same conclusion [25]. Our 
study supports only one of these findings.
There are some limitations to this study. First of all, a re-
trospective design carried within a group of patients treated 
in a single hospital significantly restricts research possibilities 
and selection biases may exist. Secondly, several variables were 
obtained from postoperative pathology reports, which do not 
directly translate to preoperative setting. Finally, there might 
be underlying causes influencing values of peripheral blood 
counts, that were not recognized in routine clinical evaluation, 
and are outside of retrospective study design capabilities. 
Conclusions
NLR and TI are available, reproducible, inexpensive markers 
and might be helpful with preoperative lymph node staging 
in patients with gastric cancer qualified for perioperative treat-
ment. Combination of imaging techniques and simple markers 
derived from routine blood tests might preserve patients from 
unnecessary complications associated with neoadjuvant che-
motherapy. There is a need for further prospective, large-scale 
research in this field.
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